Frozen chemistry controls bacterial infections
By sciencedaily.com
Chemists and molecular biologists have made an unexpected discovery in infection biology. The researchers can now show that two proteins that bind to one another slow down a chemical reaction central to the course of the disease in the bacteria Yersinia pseudotuberculosis. The results have been published in the Journal of Biological Chemistry.
"The discovery paves way for new insights in the regulation of bacterial virulence. The results have given us a new opportunity to study the pathogenic ability in bacteria," says Magnus Wolf-Watz, researcher at the Department of Chemistry at Umeå University, who led the study together with Hans Wolf-Watz, professor at the Department of Molecular Biology.
Yersinia pseudotuberculosis and many similar bacteria infect humans by injecting toxins, so-called effector proteins, through a needle-like organelle called injectisome. Previous research has already shown that the protein YscU plays an important part in the regulation of effector protein transportation. YscU is unique in its ability to cleave itself in two parts, as a consequence, one of these parts is then transported out through the injectisome.
By combining biological experiments with studies on atomic level, the research team discovered that another protein, YscP, binds to YscU and regulates its self-cleaving abilities. When the proteins bound to one another, the speed of the self-cleaving was greatly reduced.
"The chemical process behind the self-cleaving was cooled down by the interaction and was hence slowed down. The result is a good example of how biology and chemistry nearly always go hand in hand and is a huge step forward. This gives us new opportunities to study the regulation of the course of diseases," says Hans Wolf-Watz.
The studies on atomic level were conducted using magnetic resonance spectroscopy at the Department of Chemistry at the NMR for Life platform, which is a national infrastructure for NMR in Sweden.
"The initial investment to fund an NMR instrument that the Kempe Foundations facilitated paved way for further funding from both the Wallenberg Foundations and SciLifeLab. Also, the protein expertise platform in our labs was of crucial importance for undertaking the research project," says Magnus Wolf-Watz.
Source: https://www.sciencedaily.com/releases/2017/03/170303100420.htm
Sunday, May 10, 2026
Over the Counter Products That Support Patients Taking Bupropion
Patients taking bupropion for depression, seasonal affective disorder, or smoking cessation often seek non-prescription options that complement their treatment. Understanding which OTC approaches provide benefit alongside bupropion and which require caution helps patients make informed self-care decisions. Omega-3 fatty acid supplements are among the most evidence-supported OTC complements to antidepressant therapy. EPA-rich fish oil has demonstrated additive benefits in depression studies when combined with antidepressant medication. Bupropion's dopaminergic and noradrenergic mechanism is distinct from the serotonergic mechanisms most omega-3 research has been paired with, but the anti-inflammatory and neurobiological properties of EPA support mood regulation pathways broadly. Standard doses of one to two grams of combined EPA and DHA daily are well tolerated without pharmacological interaction with bupropion. Magnesium supplements, particularly magnesium glycinate or magnesium threonate, support neurological function and mood regulation through pathways that complement antidepressant therapy. Adequate magnesium status is relevant for both depression management and the sleep quality that bupropion-related insomnia can disrupt. Standard doses are safe alongside bupropion for patients with normal kidney function. For patients taking bupropion for smoking cessation, nicotine replacement therapies including nicotine patches, gum, lozenges, and inhalers are sometimes used in combination with bupropion. Current guidelines support combining bupropion with nicotine replacement in some patients when monotherapy is insufficient. Patients pursuing this combination should discuss it with their provider to coordinate timing and dosing. Alcohol is one of the most important OTC consumables to limit or eliminate during bupropion therapy. Bupropion lowers the seizure threshold, and alcohol both lowers it independently and introduces the risk of abrupt withdrawal, which further reduces the seizure threshold. Patients who drink regularly should discuss this with their prescriber before starting bupropion, as dose modification or a specific reduction schedule may be needed. Caffeine in high amounts can exacerbate the insomnia and agitation that some patients experience with bupropion's activating properties. Moderating caffeine intake particularly in the afternoon and evening supports sleep quality during bupropion therapy. St. John's Wort is an OTC supplement that should not be combined with bupropion. Both substances affect noradrenergic activity, and the combination raises concern for unpredictable additive effects. Patients using St. John's Wort before starting bupropion should disclose this use and discontinue it before initiating prescription antidepressant therapy. For patients who want to identify safe and beneficial non-prescription complements to their antidepressant therapy, reviewing over the counter options combined with wellbutrin-bupropion therapy provides practical clinical guidance. For patients seeking a broader view of non-pharmacological support across antidepressant treatments, the resources at antidepressant medication and management guides offer comprehensive context.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.